Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07460232 · ClinicalTrials.gov registry record · Early Phase 1
FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease
A Early Phase 1 study, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
NCT07460232: Recruiting Early Phase 1 study, sponsored by Mayo Clinic.
NCT07460232 is a Early Phase 1 study that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 50 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07460232, a Early Phase 1 study, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate the performance \[sensitivity, specificity, accuracy\] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
Primary Outcome
Percentage of cases where surgical findings and pathology are in agreement with \[18F\]FET-PET/MRI imaging
Interventions
- DRUG Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-04-27 |
| Est. Completion | 2028-07 |
| Phase | Early Phase 1 |
What NCT07460232 shows while recruiting
NCT07460232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET is the first listed.
NCT07460232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07460232 about?
NCT07460232 is a clinical study titled "FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease". The purpose of this research is to evaluate the performance \[sensitivity, specificity, accuracy\] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.
What is the current status of trial NCT07460232?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2026-04-27. Estimated completion is 2028-07.
What interventions are being tested in trial NCT07460232?
The interventions under investigation include: Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET (DRUG).
Who is sponsoring clinical trial NCT07460232?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07460232's enrollment target sits among peer trials
50 493rd of 2000 higher than 1,468 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI